SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-21-063956
Filing Date
2021-05-10
Accepted
2021-05-10 17:00:17
Documents
13
Period of Report
2021-05-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2115779d1_8k.htm   iXBRL 8-K 25806
5 EXHIBIT 99.1 tm2115779d1_ex99-1.htm EX-99.1 47384
  Complete submission text file 0001104659-21-063956.txt   257315

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA mrsn-20210510.xsd EX-101.SCH 3184
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrsn-20210510_lab.xml EX-101.LAB 34592
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrsn-20210510_pre.xml EX-101.PRE 22709
6 EXTRACTED XBRL INSTANCE DOCUMENT tm2115779d1_8k_htm.xml XML 3602
Mailing Address 840 MEMORIAL DRIVE CAMBRIDGE MA 02139
Business Address 840 MEMORIAL DRIVE CAMBRIDGE MA 02139 617-498-0020
Mersana Therapeutics, Inc. (Filer) CIK: 0001442836 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38129 | Film No.: 21908149
SIC: 2834 Pharmaceutical Preparations